Glucocorticoids in the treatment of severe sepsis and septic shock

被引:55
作者
Annane, D [1 ]
机构
[1] Univ Versailles, Serv Reanimat Med, Hop Raymond Poincare, APHP,Fac Med Paris Ouest, F-92380 Garches, France
关键词
adrenal cortex hormones; animal studies; clinical pharmacology; clinical trials; sepsis;
D O I
10.1097/01.ccx.0000176691.95562.43
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose of review Septic shock remains runs of the leading causes of death in intensive care units. In recent years, there is general use of low to moderate doses of corticosteroids in the treatment of septic shack. However; there are wide variations in the practical modality of this treatment, mainly with regard to patients' selection, treatment's dose, timing, route of administration, duration, and weaning. This review provides opinion-based guidelines for the use of corticosteroids in severe sepsis and septic shock. Recent findings A summary of the latest understanding of the mechanisms of action of corticosteroids and the most recent observations in the clinical and biologic responses to corticosteroids in severe sepsis and septic shock is presented. Summary In septic shock, intravenous hydrocortisone should be started immediately after a 250 mu g corticotropin test, at a dose of 200-300 mg per day. When adrenal insufficiency is confirmed, treatment should be continued at full doses for 7 days. Otherwise, hydrocortisone should be stopped. It is worth considering adding enteral fludrocortisone at a dose of 50 mu g per day for 7 days. In severe sepsis, despite growing evidence to support the use of a moderate dose of corticosteroids, the efficacy and safety of this treatment needs to be assessed in a large-scale study.
引用
收藏
页码:449 / 453
页数:5
相关论文
共 50 条
  • [31] MUKAIDA N, 1991, J IMMUNOL, V146, P1212
  • [32] OPPERT M, IN PRESS CRIT CARE M
  • [33] Distinct specificity for corticosteroid binding sites in amphibian cytosol, neuronal membranes, and plasma
    Orchinik, M
    Matthews, L
    Gasser, PJ
    [J]. GENERAL AND COMPARATIVE ENDOCRINOLOGY, 2000, 118 (02) : 284 - 301
  • [34] Orlikowski D, 2003, CRIT CARE MED, V31, pA124
  • [35] NEGATIVE TRANSCRIPTIONAL REGULATION OF HUMAN INTERLEUKIN-2 (IL-2) GENE BY GLUCOCORTICOIDS THROUGH INTERFERENCE WITH NUCLEAR TRANSCRIPTION FACTORS AP-1 AND NF-AT
    PALIOGIANNI, F
    RAPTIS, A
    AHUJA, SS
    NAJJAR, SM
    BOUMPAS, DT
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) : 1481 - 1489
  • [36] PAYA D, 1993, CIRC SHOCK, V41, P103
  • [37] PEREZ SA, 2005, IN PRESS BLOO
  • [38] PERRETTI M, 1993, J IMMUNOL, V150, P992
  • [39] Science review: Mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids
    Prigent, H
    Maxime, V
    Annane, D
    [J]. CRITICAL CARE, 2004, 8 (04) : 243 - 252
  • [40] GLUCOCORTICOIDS INHIBIT THE EXPRESSION OF AN INDUCIBLE, BUT NOT THE CONSTITUTIVE, NITRIC-OXIDE SYNTHASE IN VASCULAR ENDOTHELIAL-CELLS
    RADOMSKI, MW
    PALMER, RMJ
    MONCADA, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (24) : 10043 - 10047